President Trump has signed an executive order directing cannabis to move from a Schedule I drug to a Schedule III drug. And while it has yet to be fully enacted, this is a meaningful and long-awaited shift for the cannabis industry, cannabis science, and federal policy.
Is this full legalization? No.
Is it descheduling? Not yet.
But cannabis reform has never been a single leap forward. It has always been incremental. And this move, especially when it comes to taxation and research, represents one of the most significant actions the federal government has taken in decades. Progress may be imperfect, but it is still progress, and this one really matters.
The Biggest Immediate Win: Relief From 280E
From a business perspective, the most immediate and impactful result of moving cannabis to Schedule III is tax relief.
Under IRS Tax Code 280E, businesses trafficking Schedule I or II substances have been barred from deducting most ordinary and necessary business expenses, including payroll, rent, marketing, utilities, and administrative costs. For cannabis operators, this has meant effective tax rates often exceeding 60–65%, even while operating legally at the state level.
Schedule III substances are not subject to 280E.
That distinction alone has the potential to fundamentally change the economics of the cannabis industry. Cannabis businesses may now be able to deduct ordinary expenses like any other company — a long-overdue correction for an industry that has operated under uniquely punitive rules.
What Ending 280E Could Unlock for Operators
Relief from 280E could be transformative across the cannabis ecosystem:
- Improved profitability: For many operators, 280E has been the single biggest threat to survival. Removing it could immediately stabilize margins.
- More sustainable pricing: Businesses may no longer need to inflate prices just to cover excessive tax burdens.
- Reinvestment and growth: Operators can reinvest capital into hiring, training, technology, product development, and research.
- Stronger financial health: Improved balance sheets make cannabis businesses more attractive to lenders, investors, and long-term partners.
For dispensaries, cultivators, manufacturers, and brands alike, Schedule III brings the industry closer to operating on equal footing with other regulated sectors.
What the Executive Order Signals
Beyond taxes, the executive order sends an important message about how the federal government is beginning to view cannabis.
Among its key acknowledgments:
- Medical value is recognized: The order explicitly acknowledges that cannabis has accepted medical use – a direct rejection of the Schedule I classification.
- A clear distinction from Schedule I drugs: Schedule I substances are defined as having no medical use and high abuse potential. Cannabis, according to the administration, does not meet that standard and qualifies for Schedule III.
- Millions of patients matter: More than 6 million registered medical cannabis patients are finally acknowledged at the federal level.
- Public health data is considered: Research cited shows cannabis use is associated with reduced opioid use and improved outcomes for seniors.
- Hemp-derived cannabinoids are included: The order signals future regulatory clarity for hemp-derived cannabinoid products.
A Breakthrough Moment for Research and Medical Science
One of the most promising long-term outcomes of rescheduling to Schedule III is expanded access to scientific and medical research.
For decades, Schedule I classification severely limited cannabis research. Universities, hospitals, and researchers faced extraordinary barriers, from product access to regulatory approval.
Rescheduling to Schedule III is expected to:
- Reduce barriers for federally approved research
- Enable more clinical trials and peer-reviewed studies
- Improve standards of care for patients
- Accelerate research into chronic pain, opioid alternatives, and senior health
As the White House has emphasized, this executive order is specifically aimed at making it easier to study marijuana and CBD for medical purposes — a win for patients, providers, and evidence-based policymaking.
What This Change Doesn’t Do, Yet
It’s still important to be clear about the limits of this moment.
Rescheduling cannabis to Schedule III does not:
- Federally legalize cannabis
- Legalize nationwide homegrow or cultivation
- Automatically expunge past convictions
- Release anyone currently incarcerated for cannabis offenses
These gaps explain why some advocates remain frustrated, and why the push for descheduling continues. Those concerns are valid and necessary.
Why This Moment Still Matters
Is Schedule III the final goal? No.
Is there more work ahead? Without question.
But after decades of federal inertia, this move represents real, measurable progress, especially in the areas that most directly affect business sustainability and medical advancement.
Ending 280E alone could help stabilize operators, preserve jobs, encourage innovation, and create a healthier, more resilient industry.
Rescheduling may not be the finish line, but it’s a meaningful step forward. And in an industry that’s fought for every inch of progress, that’s something that deserves to be acknowledged, built upon, and celebrated. 🌿
If you’re a cannabis operator trying to understand how Schedule III and potential 280E relief could affect your business, now is the time to start planning. We’re here to help you think through pricing, margins, and next steps as this transition unfolds.
